Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Stealth BioTherapeutics Corp is a biotechnology business based in the US. Stealth BioTherapeutics shares (MITO) are listed on the NASDAQ and all prices are listed in US Dollars. Stealth BioTherapeutics employs 29 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.15|
|52-week range||$1.06 - $2.48|
|50-day moving average||$1.37|
|200-day moving average||$1.37|
|Wall St. target price||$3.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-8.73%|
|1 month (2021-09-27)||-18.44%|
|3 months (2021-07-27)||-14.81%|
|6 months (2021-04-27)||-8.00%|
|1 year (2020-10-27)||-24.14%|
|2 years (2019-10-25)||-81.80%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Revenue TTM||$21.1 million|
|Gross profit TTM||$21.1 million|
|Return on assets TTM||-83.02%|
|Return on equity TTM||-1666.63%|
|Market capitalisation||$67.9 million|
TTM: trailing 12 months
There are currently 1.1 million Stealth BioTherapeutics shares held short by investors – that's known as Stealth BioTherapeutics's "short interest". This figure is 29.8% up from 853,165 last month.
There are a few different ways that this level of interest in shorting Stealth BioTherapeutics shares can be evaluated.
Stealth BioTherapeutics's "short interest ratio" (SIR) is the quantity of Stealth BioTherapeutics shares currently shorted divided by the average quantity of Stealth BioTherapeutics shares traded daily (recently around 483665.50218341). Stealth BioTherapeutics's SIR currently stands at 2.29. In other words for every 100,000 Stealth BioTherapeutics shares traded daily on the market, roughly 2290 shares are currently held short.
However Stealth BioTherapeutics's short interest can also be evaluated against the total number of Stealth BioTherapeutics shares, or, against the total number of tradable Stealth BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stealth BioTherapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Stealth BioTherapeutics shares in existence, roughly 20 shares are currently held short) or 0.0494% of the tradable shares (for every 100,000 tradable Stealth BioTherapeutics shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Stealth BioTherapeutics.
Find out more about how you can short Stealth BioTherapeutics stock.
We're not expecting Stealth BioTherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Stealth BioTherapeutics's shares have ranged in value from as little as $1.06 up to $2.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stealth BioTherapeutics's is 1.8838. This would suggest that Stealth BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.